Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical
condition characterized by dyspnea and functional impairment. HFrEF has a high burden of …

The immune system is intimately involved in the pathophysiology of heart failure. However, it
is currently underused as a therapeutic target in the clinical setting. Moreover, the …

Background: Major gaps exist in the routine initiation and dose up-titration of guideline-
directed medical therapies (GDMT) for patients with heart failure with reduced ejection …

Background Beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI),
mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors …

Background Guideline-directed medical therapy (GDMT) optimization is mandatory before
transcatheter edge-to-edge mitral valve repair (M-TEER) in patients with secondary mitral …

Randomized controlled trials (RCTs) have established the efficacy of several therapies to
improve both symptoms and outcomes for patients with heart failure and reduced left …

Guideline‐directed medical therapy (GDMT) has the potential to reduce the risks of mortality
and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

Aim Patients with heart failure with reduced ejection fraction and low systolic blood pressure
(SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical …

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested …

The advent of newly available medical therapies for heart failure with reduced ejection
fraction (HFrEF) has resulted in many potential therapeutic combinations, increasing …